SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-024168
Filing Date
2023-08-18
Accepted
2023-08-18 16:17:30
Documents
14
Period of Report
2023-08-17
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbyi20230817_8k.htm   iXBRL 8-K 29361
2 EXHIBIT 3.1 ex_562321.htm EX-3.1 160639
  Complete submission text file 0001437749-23-024168.txt   360241

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20230817.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbyi-20230817_def.xml EX-101.DEF 11804
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20230817_lab.xml EX-101.LAB 15848
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20230817_pre.xml EX-101.PRE 12019
8 EXTRACTED XBRL INSTANCE DOCUMENT pbyi20230817_8k_htm.xml XML 2665
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 231186075
SIC: 2834 Pharmaceutical Preparations